Overexpression of HER2 is associated with offensive tumor behavior and poor clinical consequences and can be linked as a prognostic factor in the prediction of treatment with the anti-HER2 monoclonal antibodies of trastuzumab and pertuzumab as well as a target for molecular therapies [69, 70]. The gene discussed is ERBB2; the disease is neoplasm.